Brookfield Business Partners September 25, 2025 Powering Our Next Wave of Growth Anuj Ranjan, CEO, Brookfield Business Partners Enabling the Movement of Money Globally Jaspreet Dehl, CFO, Brookfield Business Partners Key Takeaways and Q&A Anuj Ranjan, CEO, Brookfield Business Partners Powering Our Next Wave of Growth Anuj Ranjan CEO, Brookfield Business Partners BBU is a large and valuable investment in Brookfield's private equity business BROOKFIELD.COM 4 25+ year private equity track record of exceptional ...

Forward Looking Statements This presentation contains certain statements that may be deemed "forward-looking statements". All statements in this document, other than statements of historical fact, that address events or developments that CEMATRIX ("the Company") expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates ...

ANALYST & INVESTOR DAY 2025 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein are forward-looking statements. Such forward-looking statement ...

Third Quarter 2025 Conference Call September 25, 2025 ® 2025 H.B. Fuller Title Slide Disclosure ® 2025 H.B. Fuller Third Quarter Highlights Adjusted EBITDA $171M Up 3% YOY Adjusted EBITDA Margin 19.1% Up 110 bps YOY Safe Harbor Statement Certain matters discussed today are forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements reflect our ...

业绩总结 - mRNA-4157/V940与KEYTRUDA联合使用的复发无生存率为74.8%，而KEYTRUDA单独使用为55.6%[12] - 在34.9个月的中位随访中，mRNA-4157/V940与KEYTRUDA联合使用降低复发或死亡风险49%[14] - 在约3年的随访中，mRNA-4157/V940与KEYTRUDA联合使用在远处转移无生存率方面显示出62%的风险降低[17] 用户数据 - mRNA-4157/V940与KEYTRUDA联合使用的治疗相关不良事件发生率为100%，而KEYTRUDA单独使用为82%[18] - mRNA-4157/V940在与KEYTRUDA联合使用时，34.6%的患者出现3级及以上不良事件，而KEYTRUDA单独使用为36%[18] 未来展望 - mRNA-4157/V940的临床试验在2026年将提供5年随访数据[11] - mRNA-4157/V940的III期试验已完全招募，参与者约为1,089人[21] - mRNA-4359正在进行的I/II期研究中，计划招募更多适应症[27] - mRNA-4203的I期研究设计为剂量递增，已对15名患者进行给药[51]

▼ MALIBU BOATS, INC." Leading the Future of Marine INVESTOR DAY September 2025 Forward Looking Statements This presentation includes froward-looking statements (as such term is defined in the Pivate Securities Litigation Reform Act of 1995). Forward-looking statements can be i and phrases as "believes," "anticipates," "oкpects," "ntends," "will," "should," continue" and similar expressions, comparable terminology or the negative thereof, and inc statements in this presentation regardingt future events, pote ...

Investor Day 2025 September 25, 2025 Forward-Looking Statements and Disclaimer This presentation includes certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Other than statements of historical facts, all statements contained in this presentation and accompanying oral commentary, including, but not limited to, statements about Klaviyo's financial outlook, long-term financial targets, and Klaviyo's expectat ...

业绩总结 - 非GAAP毛账单达到227亿美元，同比增长12%[6] - 非GAAP稀释每股收益为3.58美元，同比增长25%[6] - 第三季度GAAP收入为157亿美元，同比增长7%[8] - 非GAAP运营收入为4.75亿美元，同比增长21%[8] - 公司在2025财年第三季度的收入为15,650,924千美元，同比增长6.6%[66] - 2025年第三季度的收入为156.51亿美元，较2024年的146.85亿美元增长了6.5%[69] - 非GAAP毛账单为227.31亿美元，较2024年的202.82亿美元增长了12.1%[69] - 毛利润为11.30亿美元，较2024年的9.61亿美元增长了17.6%[75] - 非GAAP净收入为296,244千美元，同比增长18.2%[87] - 自由现金流为213,920千美元，同比下降37.0%[92] 用户数据 - 美洲地区非GAAP毛账单为142亿美元，同比增长9%[10] - 欧洲地区非GAAP毛账单为69亿美元，同比增长14.9%[10] - 亚太地区非GAAP毛账单为17亿美元，同比增长29.7%[10] - 公司在美洲地区的收入为9,267,939千美元，同比增长2.0%[66] - 公司在欧洲地区的收入为5,174,835千美元，同比增长12.7%[66] - 公司在亚太地区的收入为1,208,150千美元，同比增长20.4%[66] 未来展望 - 第四季度预计非GAAP毛账单在230亿至240亿美元之间[11] - 公司计划到2045年实现净零温室气体排放[54] - 2025年8月31日的非GAAP净收入预期为281千美元至322千美元[99] 成本与费用 - 销售第三方供应商服务合同、软件即服务安排及某些履行合同相关的成本为70.80亿美元，较2024年的55.98亿美元增长了26.5%[69] - 调整后的销售、一般和行政费用为6.55亿美元，较2024年的5.68亿美元增长了15.4%[80] - 非GAAP收入成本为216.01亿美元，较2024年的203.01亿美元增长了3.9%[78] 财务指标 - 截至2025年8月，现金余额为8.74亿美元，总流动性为56.29亿美元[30] - 2025年8月31日的有效税率为22.66%[85] - 2025年8月31日的非GAAP有效税率为22.96%[85] - 2025年8月31日的调整后EBITDA为504,224千美元，较2025年5月31日的444,348千美元增长13.5%[108] - 2025年8月31日的总借款为4,238,842千美元，较2025年5月31日的4,105,705千美元增长3.2%[105] - 2025年8月31日的净债务为3,364,492千美元，较2025年5月31日的3,338,606千美元增长0.8%[105] 其他信息 - 公司在2025财年第三季度的毛利率为92%[45] - 公司在2025财年第三季度的应收账款天数(DSO)为39天[50] - 2025年第三季度的毛利率为7.22%，较2024年的6.54%有所提升[75] - 2025年8月31日的存货为9,137,505千美元，较2025年5月31日的8,655,741千美元增长5.5%[96] - 2025年8月31日的应付账款为15,651,286千美元，较2025年5月31日的14,542,575千美元增长7.6%[96]

Among the factors that could cause actual results and outcomes to differ materially from those contained in the forward-looking statements are the following: changes in the competitive landscape and/or our failure to successfully adjust to such changes; changes in general or regional U.S. economic conditions, including economic downturns, inflationary pressures, fluctuating interest rates, tariffs or the effect of trade policies, and the potential impact of international events; changes in the availability ...

BUILDING THE NEXT COPPER-GOLD GIANT High-Grade, High-Impact, Strategically Positioned NO GUTS, NO GLORY TSX: NGEX OTCQX: NGXXF NGEXminerals.com Investor Day Presentation | September 25, 2025 Cautionary Statement Certain statements made and information contained herein in the presentation constitutes "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation (collectively, "forward-looking information"). The forward-looking information contained in ...